Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchiveElevance Health 3Q Benefit Expense Ratio 90.6%

Live News EQUITY FLASH L impact Oct 21, 2026, 10:00 AM UTC

Elevance Health 3Q Benefit Expense Ratio 90.6%

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

ELV

Related stories

FIIs Sell ₹3,459 Crore of Indian Stocks as Market Falls for Third Straight Session FIIs were net sellers of Indian equities worth ₹3,458.70 crore on October 22, according to provisional data. DIIs were net buyers worth ₹2,891.32 crore. M impact | EQUITY | Oct 22, 2026, 01:03 PM UTC Climb Global Solutions to Acquire French IT Distributor NeoVAD for About €16 Million Climb Global Solutions entered into an agreement to acquire all outstanding shares of NeoVAD for approximately €16.0 million, subject to adjustments. NeoVAD is a France-based value M impact | EQUITY | Oct 22, 2026, 01:03 PM UTC NVR Q3 Net Income Falls 27% as Revenue Declines NVR reported Q3 2026 net income of $248.6 million, or $89.45 diluted EPS, down 27% year over year. Revenue was $2.40 billion versus $2.61 billion, while homebuilding gross margin f M impact | EQUITY | Oct 22, 2026, 01:01 PM UTC Genasys Receives $5M U.S. Army Order Genasys received a $5 million U.S. Army order for mobile emergency warning systems. M impact | EQUITY | Oct 22, 2026, 01:01 PM UTC Cardlytics to Report Q3 2026 Results After Market Close Nov. 5 Cardlytics said it will release results for the quarter ended Sept. 30, 2026, after market close on Nov. 5, 2026. M impact | EQUITY | Oct 22, 2026, 01:01 PM UTC AbbVie Says Experimental Skin Drug Met Main Goal in Late-Stage Trial AbbVie said lutikizumab significantly reduced inflammatory lumps and abscesses in patients with a chronic skin disease. The late-stage study met its main goal. M impact | EQUITY | Oct 22, 2026, 01:00 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Market Context
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.